KMT2D and cancer: The genetic landscape was shown to be different in early stage vs. advanced stage cancers, with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), phosphatase and tensin homolog (PTEN), lysine methyltransferase 2D (MLL2), titin (TTN) being the most popular concurrent altered genes [9].